Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00735852|
Recruitment Status : Completed
First Posted : August 15, 2008
Last Update Posted : April 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Endometriosis||Drug: Decapeptyl SR 11.25mg||Phase 4|
A screening visit,will be performed and written informed consent will be obtained from the patient. In addition the patient's medical history will be checked, vital signs recorded, pain and general health questionnaires completed, blood samples collected and any prior or concomitant medications will be noted. Bone density will be determined using a DEXA scan performed in the interval between the screening and baseline visits. One month after the screening visit, patients will return to the clinic for the baseline visit. At this visit a physical examination and urine pregnancy test will be performed, vital signs measured, specific validated questionnaires on pain and endometriosis related health will be completed and symptoms of oestrogen deficiency will be documented. Patients who are still considered to be eligible for the trial will receive an injection of Decapeptyl SR 11.25 mg, and will be dispensed sufficient Livial 2.5 mg tablets to last until the next study visit. Patients will return for repeat Decapeptyl SR injections every 3 months until Month 21 at which time the last Decapeptyl SR injection will be administered. At these visits patients will also be dispensed further supplies of Livial.
Follow−up assessments will be performed during the treatment period 3, 6, 12, 18 and 24 months after the baseline visit. A final follow−up assessment will be conducted 6 months after stopping treatment. At each follow−up visit specific validated questionnaires on pain and endometriosis related health will be collected and symptoms of oestrogen deficiency will be noted. Physical examination, vital signs, bone density assessment and haematology and biochemistry analysis will be repeated at selected timepoints.
Health economic data will be collected at all study visits.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Drug: Decapeptyl SR 11.25mg
11.25 mgs, Intra muscular (IM) every 3 months for 2 yearsOther Name: Triptorelin acetate
- To assess the impact of treatment with Decapeptyl SR plus Livial on CCPP throughout the 24 month treatment period [ Time Frame: baseline, month 12, month 24 and month 30 ]
- To asses effect of Decapeptyl SR on pain, disability, overall health status and quality of life [ Time Frame: baseline and 3 monthly until study end ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00735852
|Academic Unit of Reproductive and Developmental Medicine, Jessop Wing, Tree Root Walk|
|Sheffield, South Yorkshire, United Kingdom, S13 8LE|
|Principal Investigator:||Mostafa Metwally, Mr||Sheffield Teaching Hopsitals Trust|